5.86
price down icon7.57%   -0.48
after-market Dopo l'orario di chiusura: 5.86
loading
Precedente Chiudi:
$6.34
Aprire:
$6.17
Volume 24 ore:
369.59K
Relative Volume:
1.78
Capitalizzazione di mercato:
$296.33M
Reddito:
-
Utile/perdita netta:
$-76.41M
Rapporto P/E:
-3.0521
EPS:
-1.92
Flusso di cassa netto:
$-64.56M
1 W Prestazione:
-16.29%
1M Prestazione:
-21.76%
6M Prestazione:
-34.23%
1 anno Prestazione:
-25.35%
Intervallo 1D:
Value
$5.72
$6.455
Intervallo di 1 settimana:
Value
$5.72
$7.25
Portata 52W:
Value
$5.72
$12.38

Aura Biosciences Inc Stock (AURA) Company Profile

Name
Nome
Aura Biosciences Inc
Name
Telefono
(617)500-8864
Name
Indirizzo
80 GUEST STREET, BOSTON
Name
Dipendente
106
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-24
Name
Ultimi documenti SEC
Name
AURA's Discussions on Twitter

Confronta AURA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AURA
Aura Biosciences Inc
5.86 296.33M 0 -76.41M -64.56M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-25 Iniziato H.C. Wainwright Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-04-17 Ripresa BTIG Research Buy
2022-07-19 Iniziato JMP Securities Mkt Outperform

Aura Biosciences Inc Borsa (AURA) Ultime notizie

pulisher
12:32 PM

Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com

12:32 PM
pulisher
09:31 AM

Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com

09:31 AM
pulisher
Mar 28, 2025

Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com

Mar 27, 2025
pulisher
Mar 26, 2025

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology

Mar 26, 2025
pulisher
Mar 26, 2025

Bel-sar shows promising safety, efficacy in NMIBC - Urology Times

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences Reports Progress in Cancer Trials - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 19, 2025

Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN

Mar 16, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 03, 2025

Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to present new bladder cancer study data - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Will Aura's Bladder Cancer Treatment Change Patient Outcomes? New Data Coming in 2025 - StockTitan

Mar 03, 2025
pulisher
Feb 25, 2025

How to Take Advantage of moves in (AURA) - news.stocktradersdaily.com

Feb 25, 2025
pulisher
Feb 25, 2025

Syndax Announces Participation in March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

How Will Aura Biosciences Address Investors at Two Major Healthcare Conferences Next Month? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer: Key Trend Transfo... - WhaTech

Feb 24, 2025

Aura Biosciences Inc Azioni (AURA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):